Aurobindo gets Canadian nod for antibiotic

Image
BS Reporter Mumbai
Last Updated : Jan 21 2013 | 2:08 AM IST

Hyderabad-based Aurobindo Pharma has today announced that the company has received an approval from Canada for its antibiotic drug. The drug is called Cefuroxime Axetil Tablets, and is the generic version of GlaxoSmithKline's Ceftin Tablets. Aurobindo has received approval to market 250 mg and 500 mg versions of the drug. Ceftin Tablets is used to treat patients with mild to moderate infections.

This is Aurobiondo's eighth approval from Health Canada. The company has a wide-spread international presence and markets its products across 125 countries. Its manufacturing facilities are approved by various regulatory agencies from US, Canada, Brazil and South Africa.

Aurobindo manufactures both generic medicines and active pharmaceutical ingredients. Apart from antibiotics, Aurobindo has products across different areas of medicine like anti-retrovirals, anti-allergins, gastro-enterologicals, cardiovascular drugs.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 03 2010 | 2:17 PM IST

Next Story